Drugs / [C-11]T-1650
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03861000 | Mar 2019 → Feb 2020 | depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [C-11]T-1650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03861000 ↗ |
| Known as | 11C-T-1650 | “We have developed a PET ligand, 11C-T-1650, to selectively image PDE4D.” NCT03861000 ↗ |
| Modality | Diagnostic / imaging agent | “we have developed a PET ligand, 11C-T-1650, to selectively image PDE4D.” NCT03861000 ↗ |
| Route | Intravenous | “10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan.” NCT03861000 ↗ |
| Target | PDE4D | “to selectively image PDE4D” NCT03861000 ↗ |